Loss of the Non-Canonical BAF Complex as a Driver and Therapeutic Target in SF3B1-Mutant MDS and Leukemia


IN PARTNERSHIP WITH LEUKEMIA & LYMPHOMA SOCIETY AND THE PAUL G. ALLEN FRONTIERS GROUP (2020-PRESENT)

Dr. Bradley is investigating comprehensively the mutations in the SF3B1 protein and their connection with myelodysplastic syndromes (MDS) and leukemias and exploring this protein as a therapeutic target.

BACK TO OUR PORTFOLIO